GSK at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
GSK exhibits at Booth 1739 at ASH 2026 in New Orleans. Its presence centres on myelofibrosis and multiple myeloma, supporting symposia on where myelofibrosis care is heading and on real-world care in myeloproliferative neoplasms. It also supports a symposium answering community oncologists' questions about BCMA-directed antibody-drug conjugates and bispecific antibodies in myeloma.
| Organization | ASH 2026 Attendance |
|---|---|
GSK London, United Kingdom | |
Global pharmaceutical company whose oncology focus includes blood cancers, with medicines for myelofibrosis and multiple myeloma. | Booth Exhibiting at Booth 1739 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 3:00pm–6:00pm A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We’re Going Real patient cases showing how experts treat myelofibrosis today, paired with reviews of current data and ongoing research on emerging therapies. Symposium Fri Dec 11 7:00pm–10:00pm Addressing Community Oncologists’ Questions About BCMA-Directed Antibody-Drug Conjugates and Bispecific Antibodies in Multiple Myeloma – What Clinicians Want To Know Answers to community oncologists' top questions on B-cell maturation antigen-targeted antibody-drug conjugates and bispecific antibodies in multiple myeloma. Symposium Fri Dec 11 3:00pm–6:00pm Cases and Conversations™: Applying Emerging Evidence to Real-World Care in Myeloproliferative Neoplasms Choosing among new myeloproliferative neoplasm drugs, including Janus kinase and telomerase inhibitors, hepcidin mimetics, and calreticulin-targeted antibodies. |
Instantly find 20 buyers from GSK
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction